{"schema_version":"secwatch.filing_event.v1","accession":"0000950170-23-010303","form_type":"8-K","ticker":"KOD","cik":"0001468748","company_name":"Kodiak Sciences Inc.","filed_at":"2023-03-28T23:59:59+00:00","discovered_at":"2026-05-14T18:03:45.124438+00:00","generated_at":"2026-06-17T12:36:47.259127+00:00","sec_items":["2.02","9.01"],"event_type":"earnings","sentiment":"neutral","materiality_score":0.65,"calibrated_materiality_score":0.65,"confidence":"high","headline":"Kodiak Sciences Q4 net loss $70.4M ($1.35/sh); cash $478.9M; tarcocimab data Q3 2023","bullets":["Cash, equivalents and marketable securities totaled $478.9M at Dec 31, 2022.","Q4 2022 net loss $70.4M ($1.35/sh) vs Q4 2021 net loss $93.2M ($1.79/sh).","R&D expenses $56.0M in Q4 2022, down from $75.6M; G&A $18.1M vs $17.5M.","Topline data from 4 Phase 3 tarcocimab studies (DME, NPDR, wAMD) expected Q3 2023.","KSI-501 Phase 1 in DME screening patients; commercial cGMP manufacturing started at Ursus."],"urls":{"canonical":"https://secwatch.observer/filing/0000950170-23-010303","json":"https://secwatch.observer/filing/0000950170-23-010303.json","markdown":"https://secwatch.observer/filing/0000950170-23-010303.md","text":"https://secwatch.observer/filing/0000950170-23-010303.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/1468748/000095017023010303/0000950170-23-010303-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1468748/000095017023010303/kod-20230328.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-06-17T12:36:47.259127+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[{"claim_id":"dcaf3cabc9e5b1933a87084b8c9e30280933b916","claim":"Kodiak Sciences Inc. reported financial results for the fourth quarter ended December 31, 2022.","evidence_excerpt":"Kodiak Sciences Inc. (Nasdaq: KOD), a biopharmaceutical company committed to researching, developing and commercializing transformative therapeutics to treat high prevalence retinal diseases, today reported business highlights and financial results for the fourth quarter ended December 31, 2022.","evidence_source":"SEC 8-K Item 2.02","evidence_url":"https://www.sec.gov/Archives/edgar/data/1468748/000095017023010303/0000950170-23-010303-index.htm","confidence":0.9,"family_label":"Earnings Releases","details":[{"label":"Period","value":"the fourth quarter ended December 31, 2022"},{"label":"Result","value":"reported results"}],"fact_type":"earnings_release"}],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}